[{"data":1,"prerenderedAt":653},["ShallowReactive",2],{"articles-all":3},[4,158,269,369,455,560],{"id":5,"title":6,"author":7,"authorTitle":8,"body":9,"date":144,"description":145,"draft":146,"extension":147,"featured":148,"heroCredit":149,"heroImage":150,"meta":151,"navigation":148,"path":152,"readingTime":153,"seo":154,"stem":155,"topic":156,"__hash__":157},"articles\u002Farticles\u002Fwhat-we-mean-when-a-drug-works.md","What we mean when we say a drug \"works\"","Higher Place editors",null,{"type":10,"value":11,"toc":134},"minimark",[12,16,24,29,32,38,41,44,48,51,54,58,61,65,81,84,88,129],[13,14,15],"p",{},"Every few months a headline announces that a psychedelic compound has produced\n\"unprecedented\" results for depression, addiction or trauma. Some of those\nresults are real and important. They are also frequently misunderstood — by\nreaders, by reporters, and sometimes by the people running the studies.",[13,17,18,19,23],{},"This is not an argument that the research is weak. Much of it is careful, and\nthe field has matured quickly. It is an argument that ",[20,21,22],"em",{},"promising"," is a specific,\nlimited claim, and that learning to hear it precisely is the most useful skill a\ncurious person can bring to this subject.",[25,26,28],"h2",{"id":27},"a-result-is-a-sentence-with-hidden-clauses","A result is a sentence with hidden clauses",[13,30,31],{},"When a trial reports that a single dose \"significantly reduced depression at\nsix weeks\", several quieter facts travel underneath that sentence: how many\npeople were studied, who they were, what the comparison group received, how\nlong anyone was followed, how the outcome was measured, and how large the\ndifference actually was.",[33,34,35],"blockquote",{},[13,36,37],{},"A number without its denominator is a rumour with a decimal point.",[13,39,40],{},"Take the largest programme in the field. Compass Pathways ran two Phase 3\ntrials of a synthetic psilocybin formulation for treatment-resistant\ndepression. The first, with 258 participants, found that a single 25 mg dose\nbeat placebo at six weeks by a mean of 3.6 points on the MADRS, a 60-point\ndepression scale. The second, with 581 participants, found that two 25 mg doses\nbeat a 1 mg comparison dose by 3.8 points. Both results were statistically\nstrong. Both are also, in absolute terms, modest: a few points on a long scale,\nin the same neighbourhood as the average gap between a conventional\nantidepressant and placebo. That is not a criticism of the trials. It is what\n\"significant\" means, and it is a long way from \"cured\".",[13,42,43],{},"Smaller studies deserve even more caution. A 2021 trial comparing psilocybin to\nthe antidepressant escitalopram enrolled 59 people and, on its main outcome,\nfound no significant difference between the two. Early-phase studies exist to\ndetect whether an effect is plausible, not to measure it accurately. The honest\nreading of an exciting early result is not \"this works\" but \"this is worth the\nexpense and risk of finding out properly\".",[25,45,47],{"id":46},"the-unblinding-problem","The unblinding problem",[13,49,50],{},"Psychedelics present researchers with an awkward fact: people generally know\nwhether they have taken one. That breaks the blind that ordinary drug trials\nrely on, and expectation is a powerful medicine in its own right. Good teams now\ndesign around this — low-dose active comparators, independent raters, careful\nmeasurement of what participants believed they received — but a study that\nignores it should be read with that gap in mind.",[13,52,53],{},"This is not a theoretical worry. In 2024 the US Food and Drug Administration\ndeclined to approve MDMA-assisted therapy for post-traumatic stress disorder,\ndespite two positive Phase 3 trials, and the difficulty of blinding was among\nthe reasons its advisers gave. Regulators were not saying the treatment does not\nwork. They were saying the trials could not yet prove how much of the effect\nwas the drug.",[25,55,57],{"id":56},"durable-is-a-claim-about-a-denominator","\"Durable\" is a claim about a denominator",[13,59,60],{},"Durability is the whole question for a treatment given once or twice. So when\na company reports that benefit \"lasted six months\", ask: among whom? In the\nCompass trials, the six-month durability data were reported for participants\nwho had already responded at week six. That is a real and useful finding. It is\nalso a different, narrower claim than \"the treatment lasts six months\", because\nit leaves out everyone for whom it did not work in the first place.",[25,62,64],{"id":63},"what-good-evidence-will-look-like","What good evidence will look like",[66,67,68,72,75,78],"ul",{},[69,70,71],"li",{},"Larger samples that include the people clinicians actually treat, not only\nthe unusually well and unusually motivated.",[69,73,74],{},"Longer follow-up of everyone enrolled, not only responders.",[69,76,77],{},"Honest accounting of harms, including the difficult or destabilising\nexperiences that averages tend to hide.",[69,79,80],{},"Results reported in absolute terms — points on a scale, proportion of people\nin remission — rather than only as \"significant\".",[13,82,83],{},"None of this is a reason for despair, and none of it is a reason for hype. The\nfield is young and, for the first time, it has large trials to argue about. The\nmost respectful thing anyone can do for it, and for the people waiting on it,\nis to describe it accurately while it grows up.",[25,85,87],{"id":86},"sources-and-further-reading","Sources and further reading",[66,89,90,93,100,106,113,119,126],{},[69,91,92],{},"Compass Pathways, COMP005 topline results (June 2025), COMP006 topline\nresults (February 2026) and COMP006 26-week results (July 2026), company\nannouncements.",[69,94,95,96,99],{},"Goodwin GM et al. \"Single-dose psilocybin for a treatment-resistant episode of\nmajor depression.\" ",[20,97,98],{},"New England Journal of Medicine",", 2022.",[69,101,102,103,105],{},"Carhart-Harris R et al. \"Trial of psilocybin versus escitalopram for\ndepression.\" ",[20,104,98],{},", 2021.",[69,107,108,109,112],{},"Raison CL et al. \"Single-dose psilocybin treatment for major depressive\ndisorder: a randomized clinical trial.\" ",[20,110,111],{},"JAMA",", 2023.",[69,114,115,116,105],{},"Muthukumaraswamy SD, Forsyth A, Lumley T. \"Blinding and expectancy confounds\nin psychedelic randomized controlled trials.\" ",[20,117,118],{},"Expert Review of Clinical\nPharmacology",[69,120,121,122,125],{},"Aday JS et al. \"Great expectations: recommendations for improving the\nmethodological rigor of psychedelic clinical trials.\" ",[20,123,124],{},"Psychopharmacology",",\n2022.",[69,127,128],{},"US FDA, Psychopharmacologic Drugs Advisory Committee meeting on midomafetamine\n(MDMA) for PTSD, June 2024; complete response letter reported August 2024.",[13,130,131],{},[20,132,133],{},"This essay is general information, not medical advice. Trial results and\nregulatory status change; check current sources before relying on any figure\nhere.",{"title":135,"searchDepth":136,"depth":136,"links":137},"",3,[138,140,141,142,143],{"id":27,"depth":139,"text":28},2,{"id":46,"depth":139,"text":47},{"id":56,"depth":139,"text":57},{"id":63,"depth":139,"text":64},{"id":86,"depth":139,"text":87},"2026-05-12","Psychedelic trials report dramatic numbers. Understanding what those numbers measure — and what they quietly leave out — is the first step to reading them honestly.",false,"md",true,"Higher Place — original artwork","\u002Fimg\u002Fheroes\u002Fresearch-science.svg",{},"\u002Farticles\u002Fwhat-we-mean-when-a-drug-works",9,{"title":6,"description":145},"articles\u002Fwhat-we-mean-when-a-drug-works","research-science","Imw7cUqmXn37TBWU8b-tiNKmzjdOz3z_r-3qb-j2jV0",{"id":159,"title":160,"author":7,"authorTitle":8,"body":161,"date":259,"description":260,"draft":146,"extension":147,"featured":146,"heroCredit":149,"heroImage":261,"meta":262,"navigation":148,"path":263,"readingTime":264,"seo":265,"stem":266,"topic":267,"__hash__":268},"articles\u002Farticles\u002Fthe-room-matters-as-much-as-the-molecule.md","The room matters as much as the molecule",{"type":10,"value":162,"toc":253},[163,166,169,173,176,180,183,188,191,195,213,216,218,248],[13,164,165],{},"Ask a researcher what makes psychedelic-assisted therapy work and you will\nrarely hear an answer that is only about pharmacology. You will hear about the\npreparation, the relationship with the people in the room, the music, the\nintention, and the weeks of conversation that follow. The drug opens a door. It\ndoes not decide what is on the other side.",[13,167,168],{},"That idea is older than the modern field. \"Set and setting\" was popularised by\nTimothy Leary and colleagues in the early 1960s, and the observation behind it —\nthat the same substance produces wildly different experiences depending on who\ntakes it, in what state, and where — runs through the whole history of\npsychedelic research. Contemporary researchers have argued that context is not\na modifier of the drug's effect but part of the effect itself.",[25,170,172],{"id":171},"preparation-is-treatment-not-paperwork","Preparation is treatment, not paperwork",[13,174,175],{},"The hours spent before a dosing session — building trust, naming fears,\nagreeing what care looks like if things become difficult — are not\nadministrative throat-clearing. They are part of the intervention. Every major\ntrial protocol builds them in, and clinicians consistently report that people\nwho arrive prepared, with a relationship already established, tend to move\nthrough hard moments rather than being overwhelmed by them.",[25,177,179],{"id":178},"setting-is-an-ethical-claim-in-disguise","\"Setting\" is an ethical claim in disguise",[13,181,182],{},"To say setting matters is to say that a vulnerable person, in an unusually open\nstate, is profoundly affected by how they are treated. That is a statement\nabout power before it is a statement about décor.",[33,184,185],{},[13,186,187],{},"The question is never only \"is this molecule safe?\" It is \"is this person safe\nin this room, with these people, under this much openness?\"",[13,189,190],{},"The field has a documented case of what happens when that question is not\ntaken seriously. In a Phase 2 MDMA trial in Canada, two therapists breached\nprofessional boundaries with a participant during a supervised session, and the\nparticipant later described further abuse after the trial ended. The case\nbecame public in 2021, along with video from the session, and it shaped the\nscrutiny regulators applied to the therapy component of later trials. It is a\nreminder that safeguards — screening, two-person care, clear boundaries,\nrecorded sessions, and a plan for the days afterward — are not optional extras.\nThey exist because the same openness that allows healing also removes the\ndefences a person would normally rely on.",[25,192,194],{"id":193},"what-this-means-if-you-are-considering-it","What this means if you are considering it",[66,196,197,204,207,210],{},[69,198,199,200,203],{},"A credible programme spends real time with you ",[20,201,202],{},"before"," any dose.",[69,205,206],{},"It can describe, concretely, what happens if you become distressed, and who\nyou can complain to if something goes wrong.",[69,208,209],{},"It never has a single person alone with you during a session.",[69,211,212],{},"It treats the weeks after the session as the main event, not the aftermath.",[13,214,215],{},"The molecule will get the headlines. The room is where the work is done.",[25,217,87],{"id":86},[66,219,220,227,234,245],{},[69,221,222,223,226],{},"Hartogsohn I. \"Constructing drug effects: a history of set and setting.\"\n",[20,224,225],{},"Drug Science, Policy and Law",", 2017.",[69,228,229,230,233],{},"Carhart-Harris RL et al. \"Psychedelics and the essential importance of\ncontext.\" ",[20,231,232],{},"Journal of Psychopharmacology",", 2018.",[69,235,236,237,240,241,244],{},"Reporting by ",[20,238,239],{},"New York Magazine"," and the ",[20,242,243],{},"Cover Story: Power Trip"," podcast\n(2021–2022) on the Canadian MDMA trial case.",[69,246,247],{},"US FDA advisory committee meeting on midomafetamine (MDMA) for PTSD, June\n2024, which discussed the therapy component and participant safety.",[13,249,250],{},[20,251,252],{},"This essay is general information, not medical advice.",{"title":135,"searchDepth":136,"depth":136,"links":254},[255,256,257,258],{"id":171,"depth":139,"text":172},{"id":178,"depth":139,"text":179},{"id":193,"depth":139,"text":194},{"id":86,"depth":139,"text":87},"2026-05-06","\"Set and setting\" is often treated as a slogan. In clinical practice it is closer to the active ingredient — and treating it casually is where harm tends to begin.","\u002Fimg\u002Fheroes\u002Fpsychedelic-therapy.svg",{},"\u002Farticles\u002Fthe-room-matters-as-much-as-the-molecule",8,{"title":160,"description":260},"articles\u002Fthe-room-matters-as-much-as-the-molecule","psychedelic-therapy","QsEDra5xC969Sc37UnE1zGBBBde4y_Iy6Yk0li7nfO0",{"id":270,"title":271,"author":7,"authorTitle":8,"body":272,"date":361,"description":362,"draft":146,"extension":147,"featured":146,"heroCredit":149,"heroImage":261,"meta":363,"navigation":148,"path":364,"readingTime":365,"seo":366,"stem":367,"topic":267,"__hash__":368},"articles\u002Farticles\u002Fintegration-is-the-real-work.md","After the session: why integration is the real work",{"type":10,"value":273,"toc":354},[274,277,281,288,293,297,308,311,315,318,322,325,332,334,350],[13,275,276],{},"People imagine the dosing session as the climax of psychedelic therapy. In\npractice, clinicians often describe it as the prologue. What a person does with\nwhat they saw — over weeks, sometimes months — is where a temporary experience\nbecomes a durable change, or fails to.",[25,278,280],{"id":279},"insight-is-not-the-same-as-change","Insight is not the same as change",[13,282,283,284,287],{},"A vivid realisation under the influence of a psychedelic can feel like an\nending: ",[20,285,286],{},"now I understand",". But understanding rarely rewrites a life on its\nown. The pattern you saw clearly at 2pm on a Tuesday still has to be met,\nagain and again, in ordinary circumstances that are far less luminous.",[33,289,290],{},[13,291,292],{},"The session shows you the room. Integration is the slow business of moving\nthe furniture.",[25,294,296],{"id":295},"what-integration-actually-involves","What integration actually involves",[66,298,299,302,305],{},[69,300,301],{},"Putting language to an experience that often resists it, without forcing it\ninto a tidy story too quickly.",[69,303,304],{},"Translating insight into small, testable changes in behaviour and\nrelationships.",[69,306,307],{},"Tending to what was disturbing as carefully as what was beautiful.",[13,309,310],{},"In clinical trials this usually takes the form of scheduled sessions with the\nsame therapists who prepared the person, in the days and weeks after dosing.\nOregon's regulated psilocybin programme requires that an integration session be\noffered after every administration. The term itself is used loosely — it can\nmean anything from structured psychotherapy to a journal and a walk — which is\none reason to ask any programme what, specifically, it means by it.",[25,312,314],{"id":313},"what-the-evidence-does-and-doesnt-say","What the evidence does and doesn't say",[13,316,317],{},"Honesty requires a caveat here. Integration is a near-universal component of\npsychedelic therapy protocols and a near-universal recommendation from\nclinicians. It has not, so far, been tested on its own: no large trial has\ncompared the same dosing session with and without integration support, so its\ncontribution cannot be separated from the rest of the package. What exists is\nclinical consensus, qualitative research on what participants found helpful,\nand the broader psychotherapy literature on turning insight into behaviour. That\nis a reasonable basis for taking it seriously. It is not proof.",[25,319,321],{"id":320},"why-going-it-alone-is-risky","Why going it alone is risky",[13,323,324],{},"The openness that makes these experiences powerful does not switch off when\nthe session ends. People can be suggestible, raw, and prone to over-reading\nmeaning in the days that follow. A good integration relationship is partly\nthere to provide ballast: someone who can hold the experience seriously without\ninflating it, and who notices early if a person is destabilising rather than\nsettling.",[13,326,327,328,331],{},"If you take one idea from this piece, let it be this: judge any programme by\nhow much it invests ",[20,329,330],{},"after"," the dose, not how impressive the dose sounds.",[25,333,87],{"id":86},[66,335,336,342,347],{},[69,337,338,339,105],{},"Gorman I et al. \"Psychedelic harm reduction and integration: a transtheoretical\nmodel for clinical practice.\" ",[20,340,341],{},"Frontiers in Psychology",[69,343,344,345,99],{},"Bathje GJ, Majeski E, Kudowor M. \"Psychedelic integration: an analysis of the\nconcept and its practice.\" ",[20,346,341],{},[69,348,349],{},"Oregon Health Authority, Oregon Psilocybin Services administrative rules\n(OAR 333-333), on integration sessions.",[13,351,352],{},[20,353,252],{},{"title":135,"searchDepth":136,"depth":136,"links":355},[356,357,358,359,360],{"id":279,"depth":139,"text":280},{"id":295,"depth":139,"text":296},{"id":313,"depth":139,"text":314},{"id":320,"depth":139,"text":321},{"id":86,"depth":139,"text":87},"2026-04-28","The dramatic part is over in a day. Whether anything changes depends on the unglamorous weeks that follow — and on having somewhere to bring what surfaced.",{},"\u002Farticles\u002Fintegration-is-the-real-work",7,{"title":271,"description":362},"articles\u002Fintegration-is-the-real-work","EDaIGvwqQR4iS4_YdNoIFdxnKDW7ZipStH4xgAAuMOI",{"id":370,"title":371,"author":7,"authorTitle":8,"body":372,"date":445,"description":446,"draft":146,"extension":147,"featured":146,"heroCredit":149,"heroImage":447,"meta":448,"navigation":148,"path":449,"readingTime":450,"seo":451,"stem":452,"topic":453,"__hash__":454},"articles\u002Farticles\u002Ftreatment-resistant-doesnt-mean-person-resistant.md","\"Treatment-resistant\" doesn't mean person-resistant",{"type":10,"value":373,"toc":439},[374,377,381,384,389,393,396,399,403,414,417,419,435],[13,375,376],{},"\"Treatment-resistant depression\" is one of the most consequential phrases in\npsychiatry, and one of the most misread. In research it usually means something\nquite specific: a person has completed at least two adequate courses of\nantidepressant treatment, at a proper dose and for a proper length of time,\nwithout enough improvement. It is a description of what has been tried. It is\nnot a verdict on the person, and the grammar matters.",[25,378,380],{"id":379},"a-description-of-medicines-not-of-patients","A description of medicines, not of patients",[13,382,383],{},"The resistance lives in the relationship between an illness and the tools\ncurrently available for it — not in some quality of the patient. People who\ncarry the label have usually done everything asked of them, often for years.\nParticipants in the recent Phase 3 psilocybin trials, for example, had been in\ntheir current depressive episode for more than three years on average and had\nlived through more than six episodes over their lives. Hearing \"resistant\" as a\npersonal failing is both inaccurate and, clinically, harmful: it adds shame to\nan illness that already manufactures it.",[33,385,386],{},[13,387,388],{},"The honest version of the term is: \"we have not yet found the thing that\nhelps you.\" That sentence keeps the door open.",[25,390,392],{"id":391},"why-this-is-the-population-in-the-trials","Why this is the population in the trials",[13,394,395],{},"Much psychedelic research recruits exactly these patients, for two reasons.\nOne is ethical: it is easier to justify an experimental treatment with unusual\nrisks for people whose standard options have run out. The other is practical:\nregulators are more willing to consider a new drug for a condition where\nnothing else has worked.",[13,397,398],{},"That should shape how the results are read. In the largest Phase 2 study, about\na third of people who received the higher dose met the definition of response\nat three weeks, and about a fifth were still responding at twelve weeks. In the\nPhase 3 trials that followed, the average benefit over comparison groups was a\nfew points on a depression scale. For a group with this history, that is\nmeaningful. It is also early, partial, and not the same as a cure. A treatment\ncan be a real improvement on \"nothing left to try\" while still helping a\nminority of the people who receive it.",[25,400,402],{"id":401},"what-it-asks-of-clinicians","What it asks of clinicians",[66,404,405,408,411],{},[69,406,407],{},"Treat the label as a prompt to keep looking, not a place to stop.",[69,409,410],{},"Be honest about uncertainty without communicating hopelessness.",[69,412,413],{},"Remember that the person has likely heard \"resistant\" as \"difficult\" — and\ncorrect that, explicitly.",[13,415,416],{},"The people these studies are built around are not hard cases. They are people\nfor whom the usual map ran out, who are still walking anyway.",[25,418,87],{"id":86},[66,420,421,428,432],{},[69,422,423,424,427],{},"Gaynes BN et al. \"Defining treatment-resistant depression.\" ",[20,425,426],{},"Depression and\nAnxiety",", 2020.",[69,429,95,430,99],{},[20,431,98],{},[69,433,434],{},"Compass Pathways, COMP005 and COMP006 Phase 3 announcements, 2025–2026.",[13,436,437],{},[20,438,252],{},{"title":135,"searchDepth":136,"depth":136,"links":440},[441,442,443,444],{"id":379,"depth":139,"text":380},{"id":391,"depth":139,"text":392},{"id":401,"depth":139,"text":402},{"id":86,"depth":139,"text":87},"2026-04-19","The clinical label describes what medicines have failed to do, not what a person is. That distinction changes how we read the research — and how we treat the people in it.","\u002Fimg\u002Fheroes\u002Fdepression-anxiety.svg",{},"\u002Farticles\u002Ftreatment-resistant-doesnt-mean-person-resistant",6,{"title":371,"description":446},"articles\u002Ftreatment-resistant-doesnt-mean-person-resistant","depression-anxiety","m3cdaXU-SZOvSEK5BxkBtLAubpqJBYwV5--b2wxdpBI",{"id":456,"title":457,"author":7,"authorTitle":8,"body":458,"date":551,"description":552,"draft":146,"extension":147,"featured":146,"heroCredit":149,"heroImage":553,"meta":554,"navigation":148,"path":555,"readingTime":264,"seo":556,"stem":557,"topic":558,"__hash__":559},"articles\u002Farticles\u002Fthe-body-keeps-the-appointment.md","The body keeps the appointment",{"type":10,"value":459,"toc":545},[460,467,471,474,479,482,486,489,492,496,507,510,512,541],[13,461,462,463,466],{},"One of the most useful shifts in trauma science over the past few decades is\nthe recognition that trauma is not stored the way a diary is. The title of this\nessay borrows from Bessel van der Kolk's ",[20,464,465],{},"The Body Keeps the Score",", the book\nthat carried that idea into ordinary conversation. The careful version of the\nclaim is not that memories are stored in the muscles. It is that the brain's\nthreat-detection systems learn from overwhelming experience and stay on duty\nlong after it — a body braced for a danger that has, in fact, already passed.",[25,468,470],{"id":469},"why-just-talk-about-it-can-fail","Why \"just talk about it\" can fail",[13,472,473],{},"Talking, reasoning and reassurance mostly engage the parts of the brain that\nwork slowly and deliberately. Much of what trauma does happens in older, faster\nsystems built to act first and ask questions never. This is why a person can\nunderstand, intellectually, that they are safe and still find their heart\nracing at a sound, a smell, a date on a calendar. The knowing and the bracing\nlive in different places.",[33,475,476],{},[13,477,478],{},"Recovery is not persuading the mind that the danger is over. It is persuading\nthe body.",[13,480,481],{},"This is not an argument against talking therapies. Trauma-focused\npsychotherapies such as prolonged exposure and EMDR remain the best-supported\ntreatments for post-traumatic stress, and they work partly by helping the body\nlearn, through repeated safe contact with the memory, that the alarm can stand\ndown. The point is that they work by changing a response, not by winning an\nargument.",[25,483,485],{"id":484},"where-new-approaches-fit","Where new approaches fit",[13,487,488],{},"MDMA-assisted therapy for PTSD is interesting precisely because it appears to\nchange the conditions under which a memory can be approached — lowering the\nalarm enough that the experience can be revisited without the body slamming the\ndoor. The therapy does the work; the drug, in this account, widens the window\nin which the work is bearable.",[13,490,491],{},"The evidence is real but unfinished. Two Phase 3 trials, with 90 and 104\nparticipants, found that around two-thirds of people who received MDMA with\ntherapy no longer met criteria for PTSD afterwards, compared with roughly a\nthird to a half of those who received therapy with placebo. In 2024 the US Food\nand Drug Administration nonetheless declined to approve the treatment, citing\nconcerns about blinding, the reporting of harms, and how the therapy component\ncould be standardised, and asked for a further trial. The mechanism described\nabove is a hypothesis under investigation, not a settled fact. But it points at\nsomething clinicians have long observed: people can often only process what\nthey are not, in that moment, drowning in.",[25,493,495],{"id":494},"what-this-means-for-expectations","What this means for expectations",[66,497,498,501,504],{},[69,499,500],{},"The aim is not erasure of memory but a changed relationship to it.",[69,502,503],{},"Bodily safety — pacing, grounding, a trusted person present — is not optional\nin any trauma treatment, with or without a drug.",[69,505,506],{},"Progress is frequently non-linear, and a hard week is not a failed treatment.",[13,508,509],{},"The body kept the appointment for years. Healing tends to mean, at last, being\nallowed to leave the waiting room.",[25,511,87],{"id":86},[66,513,514,520,526,532,535],{},[69,515,516,517,519],{},"van der Kolk B. ",[20,518,465],{},". Viking, 2014.",[69,521,522,523,105],{},"Mitchell JM et al. \"MDMA-assisted therapy for severe PTSD: a randomized,\ndouble-blind, placebo-controlled phase 3 study.\" ",[20,524,525],{},"Nature Medicine",[69,527,528,529,112],{},"Mitchell JM et al. \"MDMA-assisted therapy for moderate to severe PTSD: a\nrandomized, double-blind, placebo-controlled phase 3 trial.\" ",[20,530,531],{},"Nature\nMedicine",[69,533,534],{},"US FDA advisory committee meeting on midomafetamine (MDMA) for PTSD, June\n2024, and subsequent complete response letter, August 2024.",[69,536,537,538,427],{},"Lewis C et al. \"Psychological therapies for post-traumatic stress disorder in\nadults: systematic review and meta-analysis.\" ",[20,539,540],{},"European Journal of\nPsychotraumatology",[13,542,543],{},[20,544,252],{},{"title":135,"searchDepth":136,"depth":136,"links":546},[547,548,549,550],{"id":469,"depth":139,"text":470},{"id":484,"depth":139,"text":485},{"id":494,"depth":139,"text":495},{"id":86,"depth":139,"text":87},"2026-04-10","Trauma is not only a memory problem. Understanding why it lives in the body helps explain why some emerging therapies work on the body's terms, not the mind's alone.","\u002Fimg\u002Fheroes\u002Ftrauma-ptsd.svg",{},"\u002Farticles\u002Fthe-body-keeps-the-appointment",{"title":457,"description":552},"articles\u002Fthe-body-keeps-the-appointment","trauma-ptsd","SOayCvGrN_3jCOh72Om0Mu3yzWRQQ4futjWQg2N7sbw",{"id":561,"title":562,"author":7,"authorTitle":8,"body":563,"date":644,"description":645,"draft":146,"extension":147,"featured":146,"heroCredit":149,"heroImage":646,"meta":647,"navigation":148,"path":648,"readingTime":365,"seo":649,"stem":650,"topic":651,"__hash__":652},"articles\u002Farticles\u002Fwho-gets-to-be-a-patient.md","Who gets to be a patient?",{"type":10,"value":564,"toc":638},[565,568,572,575,580,584,587,590,594,608,611,613,633],[13,566,567],{},"Suppose the optimistic version comes true and one or more psychedelic therapies\nare approved for serious, hard-to-treat conditions. A quieter question\nimmediately follows the celebratory one: who, in practice, will actually be\nable to receive them?",[25,569,571],{"id":570},"a-labour-intensive-treatment-is-an-access-problem","A labour-intensive treatment is an access problem",[13,573,574],{},"These are not pills you collect from a pharmacy. The model under study\ninvolves trained clinicians, hours of preparation, a supervised dosing session\nthat can last most of a day, and integration over weeks. That is expensive and\nslow by design. Left to the market alone, a treatment with those properties\ntends to reach the affluent and well-connected first, and everyone else much\nlater, if at all.",[33,576,577],{},[13,578,579],{},"A therapy that only the comfortable can afford does not reduce suffering. It\nredistributes it upward.",[25,581,583],{"id":582},"the-pattern-is-already-visible","The pattern is already visible",[13,585,586],{},"This is not hypothetical. Oregon's regulated psilocybin services, open since\n2023, are paid for out of pocket, with a single supported session commonly\ncosting well over a thousand dollars, because the programme sits outside\nmedicine and no insurer covers it. Australia allowed authorised psychiatrists to\nprescribe psilocybin and MDMA from mid-2023, and the early reports were of a\nsmall number of providers charging fees in the tens of thousands of dollars.\nEsketamine, a nasal spray related to ketamine that was approved for depression\nin the United States in 2019, comes with clinic-supervised dosing and reached\npeople with good insurance first.",[13,588,589],{},"The research population tells the same story from the other end. A 2018 review\nof psychedelic trials found that more than four in five participants were\nwhite, which means the evidence base is thinnest for many of the communities\ncarrying the heaviest burden of untreated illness.",[25,591,593],{"id":592},"what-designing-for-access-looks-like","What designing for access looks like",[66,595,596,599,602,605],{},[69,597,598],{},"Training pathways that do not restrict this work to a small, costly elite.",[69,600,601],{},"Coverage decisions that consider need, not only ability to pay.",[69,603,604],{},"Research populations that resemble the people who will eventually need care,\nso the evidence actually generalises to them.",[69,606,607],{},"Regulated routes that do not depend on living in the right state or province.\nCanada's Special Access Program, for instance, has allowed physicians to\nrequest psilocybin or MDMA for individual patients since 2022, but only case\nby case and only for those who find a willing prescriber.",[13,609,610],{},"The scientific question — does it work? — is being taken seriously. The\ndistributive question — for whom? — deserves the same seriousness, and it has\nto be asked now, while the answers can still be shaped.",[25,612,87],{"id":86},[66,614,615,621,624,627,630],{},[69,616,617,618,233],{},"Michaels TI et al. \"Inclusion of people of color in psychedelic-assisted\npsychotherapy: a review of the literature.\" ",[20,619,620],{},"BMC Psychiatry",[69,622,623],{},"Oregon Health Authority, Oregon Psilocybin Services.",[69,625,626],{},"Therapeutic Goods Administration (Australia), change to classification of\npsilocybin and MDMA, effective 1 July 2023.",[69,628,629],{},"Health Canada, Special Access Program: amendments to the Food and Drug\nRegulations, January 2022.",[69,631,632],{},"US FDA approval of esketamine (Spravato) for treatment-resistant depression,\nMarch 2019.",[13,634,635],{},[20,636,637],{},"This essay is general information, not medical advice. Access rules and costs\nchange frequently; check current sources for your jurisdiction.",{"title":135,"searchDepth":136,"depth":136,"links":639},[640,641,642,643],{"id":570,"depth":139,"text":571},{"id":582,"depth":139,"text":583},{"id":592,"depth":139,"text":593},{"id":86,"depth":139,"text":87},"2026-04-02","If psychedelic therapy becomes a real treatment, the next question is not whether it works but who will be able to reach it — and whether access will follow need or money.","\u002Fimg\u002Fheroes\u002Fpolicy-access.svg",{},"\u002Farticles\u002Fwho-gets-to-be-a-patient",{"title":562,"description":645},"articles\u002Fwho-gets-to-be-a-patient","policy-access","e0_CM4bTxw7BuLHdA0xZCe1ZMz6ClhvhqHwbkF2iTH0",1791062476676]